The longevity studies cited for epitalon tested a different substance.

Why this note exists

On July 24, 2026 an FDA advisory committee voted to recommend epitalon for the 503A Bulks List — over the written recommendation of FDA's own review team, which had concluded that "a balancing of the criteria weighs against" it and proposed not adding either the free base or the acetate.[1][4] That gap between what the reviewers wrote and what the panel voted is worth reading closely, because the briefing document behind it is the most complete public audit of epitalon's evidence that exists.

In the index generated on August 15, 2026, 82 of 112 vendors carried an Epithalon listing — 135 listings, fifteenth of 83 compounds by vendor coverage.[26] Across the 77 listings the index prices per milligram, the median is $3.30/mg and the spread from cheapest to dearest is 8.4×.[26] Where a size is stated, 10 mg is the common vial (51 listings) followed by 50 mg (35); seven listings are blends, and six are capsules, oral sprays or nasal kits rather than vials.[26] The market cannot agree on the name either: 104 listings spell it Epithalon, 31 Epitalon.[26]

A note on what kind of evidence this is: this compound's file is unusually lopsided, so the labels matter more than usual. Human data are identified as human and carry their design and participant count where the source reports one. Mouse, rat and monkey studies are called animal studies in the same sentence as their result. Cell-culture work is called in vitro. Where a source reports a number without a sample size or a control, that absence is stated rather than smoothed over. pepmg does not convert a published dose into a protocol for a research vial.

The substitution

Epitalon and epithalamin are not the same thing, and FDA says so in a footnote

Almost every longevity claim attached to epitalon traces back to research from one group, the St. Petersburg Institute of Bioregulation and Gerontology. Much of that research is not about epitalon. It is about Epithalamin, a polypeptide complex extracted from cattle pineal gland; epitalon is a four-amino-acid peptide, Ala-Glu-Asp-Gly, synthesized in 1999 after calf pineal glands became hard to source.[1][21]

FDA does not treat them as interchangeable. Its evaluation states: "The nominators stated that other common names for epitalon include epithalamin(e); however, FDA considers epitalon and epithalamin as different substances. Epithalamin is a polypeptide complex extracted from the pineal gland. Epitalon is a tetrapeptide synthesized based on the study of the amino acid content of epithalamin; epitalon is considered a 'synthetic analog' of epithalamin with similar biologic effects. Epithalamin(e) is not listed as a synonym for epitalon in FDA's GSRS."[1] The nominators submitted 26 unique articles, 23 of which FDA was able to review; FDA records that seven of the submitted articles discussed epithalamin rather than epitalon, and that none discussed the use of a compounded formulation of epitalon at all.[1]

Left and centre are results for the pineal extract, not the synthetic tetrapeptide sold as Epitalon. Figures as reported in the cited abstracts; both studies come from the same research programme.

The 2003 paper is the source of the number that circulates hardest. Its abstract reports that researchers "clinically assessed the geroprotective effects" of Thymalin and Epithalamin in 266 elderly and older persons over 6 to 8 years, with the preparations given during the first 2 to 3 years, and that mortality fell 1.6 to 1.8-fold in the Epithalamin-treated group and 4.1 times in a separate group treated with both preparations annually for six years.[7] The abstract does not report randomization, blinding, or how the control group was assembled, and the intervention is the extract.[7] The 2006 companion paper describes a 12-year randomized study of epithalamine in elderly patients with coronary disease, reporting 28% fewer deaths and two-fold lower cardiovascular mortality than control — again epithalamine, and again with no participant count in the abstract.[8]

The human record

Three studies, one of them an eye injection

FDA's search of the published literature is the clearest inventory available: "After conducting a literature search, three studies were found in which epitalon was administered to humans."[1] Two gave it sublingually to shift workers — one looking at circadian gene expression, one at urinary 6-sulfatoxymelatonin, a melatonin metabolite — and neither used a compounded formulation.[1][10][11] The third gave it as a parabulbar injection to patients with congenital retinitis pigmentosa.[1][9]

The sublingual study is the best-designed human data that exists for this peptide, and it is worth stating exactly what it was. As FDA summarizes it: a randomized, placebo-controlled study in 75 healthy women aged 40 to 50 primarily working night shifts; the 40 with low 6-sulfatoxymelatonin were split into two groups and for 20 days received either placebo sprays or Ala-Glu-Asp-Gly sublingual spray, three sprays twice daily, corresponding to 0.5 mg of peptide per day.[1][10] Levels of the metabolite rose 1.7-fold in the peptide group and did not change on placebo.[1] The authors also reported "distinct positive dynamics of psycho-emotional and general physical condition in 83% of cases" against 25% on placebo — and FDA notes flatly that "no details were provided about how psycho-emotional and general physical condition were assessed."[1] FDA's other recorded limitations: the publication "did not specify blinding," the duration was short, the sample small, the study did not evaluate sleep outcomes at all, and it used the sublingual route while the nominated route was subcutaneous.[1]

The retinitis pigmentosa paper deserves the same scrutiny, because it is the only published human use of injected epitalon. Its abstract reports rat and human work in the same paragraph, and the entire human result is one sentence: "Epitalon therapy in patients with degenerative retinal lesions results in a positive clinical effect in 90% of the cases."[9] The abstract gives no number of patients, no control group, and no definition of a positive clinical effect.[9] FDA records that epitalon received an orphan drug designation for retinitis pigmentosa on September 2, 2010, and that the designation was withdrawn or revoked on January 6, 2016.[1][23]

This is a bounded negative search finding: the ClinicalTrials.gov searches linked here returned no epitalon intervention record. It does not establish that no unregistered study or record in another registry exists.[24][26] There is no approved epitalon product in the United States, and FDA records none in Canada, Australia, the United Kingdom, Belgium, Ireland, France, Germany, Spain or Italy, no EMA authorisation, and no listing in the European or Japanese Pharmacopoeia.[1][25]

The vote

FDA's reviewers said no. The panel said yes.

The Pharmacy Compounding Advisory Committee considered seven peptide families on July 23 and 24, 2026, with separate votes for the free base and the acetate salt of each; epitalon was the July 24 morning session.[3][2] The question was narrow — whether the substance belongs on the list that 503A compounders may use — and it is not a question about approval.[6]

FDA's written position was unambiguous. Its evaluation concludes that "the physicochemical characterization, limited information on historical use, lack of evidence of effectiveness, and lack of safety information identified for both epitalon (free base) and epitalon acetate weigh against their being added to the 503A Bulks List," and ends: "Accordingly, we propose not adding epitalon (free base) or epitalon acetate to the 503A Bulks List."[1] Contemporary reporting from the meeting records the committee voting 7 to 4 in favor of adding it, with FDA staff having recommended against because of the lack of clinical evidence on safety and efficacy.[4]

A sourcing note: as of August 23, 2026, FDA's meeting page for July 23–24, 2026 posts the briefing documents, the voting questions, the final agenda, the roster and the FDA presentation decks — no final summary minutes and no transcript.[2] The vote tally above is therefore contemporaneous reporting, not an FDA document, and it is labeled that way wherever it appears in this note.[4]

What a recommendation does and does not do has not changed since pepmg's note on the meeting itself. PCAC advises; FDA decides, through rulemaking, on a list that governs compounding pharmacies.[6] It does not approve a drug, and it says nothing about the contents of a vial bought online.

Animals and cells, labeled as such

The lifespan data are mouse data, from one laboratory, in female mice only

Everything in this section is non-human. Three mouse studies underpin the longevity story, all from the same research group, all in female mice, all at a single fixed dose given subcutaneously for five consecutive days each month for life, 50 mice per group.[1] In CBA mice dosed at 0.1 µg/mouse/day, spontaneous tumours fell from 10 of 50 controls to 2 of 50, and mean lifespan was 721 days against 685.[1][18] In Swiss-derived SHR mice at 1 µg/mouse/day, the lifespan of the last 10% of survivors was 803 days against 709, and leukemia incidence 1 of 50 against 6 of 50.[1][17] In HER-2/neu transgenic mice, mammary tumour number and size were reduced.[1]

FDA's cautions about that package are specific: each study used a fixed dose, so there is no dose-response; all three assessed female mice only; and the intermittent schedule meant mice were exposed for at most about 22 weeks, where a standard carcinogenicity design runs two years.[1] No two-year carcinogenicity study of epitalon exists, and FDA identified no acute-toxicity, repeat-dose-toxicity, or developmental and reproductive toxicity studies either.[1]

The melatonin story is also animal work, and it is less tidy than the marketing. In female rhesus monkeys given epitalon 2 µg/kg/day intramuscularly or saline for 10 days, older monkeys showed evening serum melatonin more than four-fold higher and evening cortisol about 30% lower, with no significant change in morning melatonin; younger monkeys showed no melatonin effect.[1][19] The authors did not assess sleep behaviour or EEG, and FDA states that it "identified no nonclinical pharmacological study assessing the effects of epitalon on sleep."[1] An in vitro study cuts the other way: acute superfusion of pineal glands from young and old rats with epitalon at 1, 10 or 100 µM failed to increase melatonin release, so the mechanism by which it changes melatonin levels in a living animal is unknown.[1][20]

The telomere claim is cell-culture work. The originating group reported in 2003 that epitalon at 50 ng/mL for four days increased telomerase expression and activity and extended telomere length in cultures of human fetal lung fibroblasts, and in 2004 that it allowed cells to divide past their usual limit.[1][12][13] A 2025 study from Brunel University London, independent of that group, reported dose-dependent telomere lengthening in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation — and telomere lengthening in the breast cancer lines 21NT and BT474 through alternative lengthening of telomeres.[14] That paper carries a published correction.[15] Both are in vitro; no completed human study has measured telomere length before and after epitalon under controlled conditions.[1]

Safety

Empty databases are not a safety record, and the mechanism cuts both ways

FDA's human safety section is four sentences long in substance. A FAERS search through December 8, 2025 retrieved no reports; a Human Foods Complaint System search through December 5, 2025 retrieved no cases; and "our search of the published medical literature has not identified clinical studies assessing the safety of epitalon-related BDSs administered in humans."[1] FDA also explains why the empty databases prove nothing: reporting is voluntary, and "[c]ompounders under section 503A of the FD&C Act generally do not report adverse events to FDA."[1] The one sublingual study that dosed 20 subjects for 20 days "did not report safety data."[1]

The mechanistic concern is the part most likely to be left out of a product page, so here it is verbatim: "from the mechanistic standpoint, epitalon has the potential to be carcinogenic. Specifically, epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer."[1] That is not a claim invented for the memo — the association between long telomeres and cancer risk has its own literature.[16] The tension is real and unresolved: the same property the market sells is the property FDA flagged, and the mouse studies that reported fewer tumours ran intermittent dosing over a fraction of a standard carcinogenicity study.[1]

Separately, FDA judged both forms "not well-characterized from the physical and chemical characterization perspective," citing naming conventions that do not follow INN, USAN or IUPAC standards and missing critical quality attributes — including that "[n]o bioburden/endotoxin test is mentioned in the CoA provided by the nominator," which it calls a critical control attribute for an injection product.[1] It flagged aggregation and immunogenicity risk specific to the injected route.[1]

The market

What was studied is 0.5 mg under the tongue. What is sold is a 10 mg vial.

The nominated compounded products were 10 mg/mL and 3000 mcg/mL for subcutaneous injection, for insomnia.[1] The only human dosing figure reproduced anywhere in FDA's evaluation is 0.5 mg per day, sublingual, for 20 days, in women aged 40 to 50 working night shifts.[1] FDA separately catalogued what wellness and concierge sites tell people, recording claims that epitalon "increases the production of telomerase," is "often referred to as 'the fountain of youth,'" and is typically taken at 5 mg to 10 mg per day by subcutaneous injection or as an oral supplement, sometimes in cycles.[1] That last figure is marketing copy FDA catalogued, not a sourced dose; it is roughly ten to twenty times the only per-day amount that appears in a human study of this peptide, by a different route.[1]

The formats match what pepmg sees. FDA found sites selling 10, 20, 25 and 50 mg vials, 3 mg and 3.3 mg capsules and an oral spray, several stating the product is intended for research use only.[1] pepmg's index on August 15, 2026 shows the same shape: 10 mg and 50 mg dominating the vials, capsules listed at 3 mg, and nasal-spray kits at the edges.[26] FDA's own conclusion on historical compounding is that "no pharmacies were found that compound products containing epitalon," and "[w]ebsites were found that sell products that contain epitalon, but it is unclear if these are compounded products."[1]

One more data point on identity, from outside the United States: in 2015 the Belgian Scientific Institute of Public Health published its identification of epitalon in two illegal pharmaceutical preparations, describing it as a "small research tetra peptide … assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa."[23] The gray market for this peptide is a decade old and has been analytically documented; the clinical file has not moved in the same period.

Where the literature is going, briefly

The volume of epitalon research is not small — a PubMed search for epitalon, epithalon or Ala-Glu-Asp-Gly returned 153 records on August 23, 2026 — but it is overwhelmingly in vitro, in silico and animal work.[27][21] A 2025 review from the Medical University of Warsaw, the most thorough recent overview, describes 25 years of study "using in vitro, in vivo, and in silico methods," reports geroprotective and neuroendocrine effects on that basis, and notes that "the quantity of physico-chemical and structural investigations of this peptide remains quite limited."[21] A 2026 narrative review of peptides in gerontology places epitalon under telomere biology and concludes that the non-approved peptides in its scope "showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation."[22] Neither is a trial, and neither claims to be.

Three things this note is not saying

First, it is not saying epitalon does nothing. Something is happening in these cell and animal models: telomerase activation in culture is reported by two independent groups two decades apart, and the monkey and mouse results are internally consistent.[12][14][19] Preclinical signal is a reason to run a trial, not a substitute for one.

Second, it is not saying the Russian research is fraudulent. It is saying two narrower things that are documented: the strongest human results are for a different substance, epithalamin, and the abstracts of those studies do not report the design details — allocation, blinding, participant counts — that would let anyone weigh them.[1][7][8]

Third, it is not saying the advisory committee was wrong to vote as it did. Compounding-list decisions balance four criteria and are not efficacy findings, and a panel is entitled to weigh them differently from staff.[6] What is worth knowing is simply that it did — and that the document the panel was voting on says the evidence of effectiveness is lacking, the safety data in humans do not exist, and the substance is not well characterized.[1]

What this note is saying is narrow: for a compound stocked by 82 of 112 vendors in this index, the entire human record is three studies, none of them in the condition it was nominated for, none by the route it is sold for, and none registered anywhere.[1][24][26]

Questions people are asking